Session Recording from PHA's 2012 10th International PH Conference
June 24, 2012
Prostacyclins (epoprostenol, treprostinil) are among the most potent and effective therapies for patients with advanced pulmonary arterial hypertension. However, there are side-effects and complications of these therapies due to their unique delivery systems. This session will review the data with the multiple infused prostacyclins currently available, focusing on patient selection and management of side effects and complications.
Vallerie McLaughlin, MD, University of Michigan, Ann Arbor, Mich. (Chair); Wendy Hill, MSN, NP-C, VA Greater LA Healthcare System/UCLA, Los Angeles, Calif.; Robert Schilz, DO, PhD, Case Western University School of Medicine, Cleveland, Ohio; Victor Tapson, MD, FCCP, FRCP, Duke University Medical Center, Durham, N.C.